Market Overview

UPDATE: Wedbush Securities Initiates Regulus Therapeutics at Outperform on Pipeline Progress

Share:
Related
Every Biotech Catalyst Wedbush Is Watching In 2016
Regulus to Present Additional Preclinical Data Supporting RG-012 as a Novel microRNA Therapeutic in Development for Alport Syndrome at ASN's Kidney Week 2015

Wedbush Securities initiated coverage on Regulus Therapeutics (NASDAQ: RGLS) with an Outperform rating and a $10 price target.

Wedbush Securities noted, "Regulus is developing oligonucleotide drugs that target microRNA, important regulators of gene expression whose dysregulation is implicated in a variety of diseases and disease states. Oligonucleotide drug discovery and development is rapid and predictable as drugs are assembled using the complementary microRNA target as a template, and other oligonucleotide drugs inform ADME, pK, safety and tolerability."

Regulus Therapeutics closed at $4.34 on Wednesday.

Latest Ratings for RGLS

DateFirmActionFromTo
Dec 2015Wells FargoInitiates Coverage onOutperform
Jun 2015Guggenheim SecuritiesInitiates Coverage onBuy
Apr 2015FBR CapitalInitiates Coverage onOutperform

View More Analyst Ratings for RGLS
View the Latest Analyst Ratings

Posted-In: Wedbush SecuritiesAnalyst Color Initiation Intraday Update Analyst Ratings

 

Related Articles (RGLS)

View Comments and Join the Discussion!

Get Benzinga's Newsletters